In an attempt to discover a phosphate binding agent for use in uraemia that would not lead to appreciable systemic absorption of aluminium the effect of sucralfate was evaluated after three weeks and compared with that of the existing standard agent aluminium hydroxide. Sucralfate caused a decrease in serum phosphate concentration comparable with that obtained with aluminium hydroxide, but similar absorption of aluminium resulted.
Introduction
Recent reports have indicated that aluminium,which is normally cleared by the kidney, may accumulate in patients receiving regular haemodialysis, resulting in extreme cases in encephalopathy or osteomalacia.1-4 Although the major source of aluminium in most series has been non-deionised water used in preparing the dialysate,5 6 a considerable contribution may come from the use of large quantities of oral aluminiumhydroxide as a phosphate binder in uraemia.7 Even in continuous ambulatory peritoneal dialysis, when the dialysate should contain minimal quantities of aluminium, appreciable increases in serum aluminium concentrations have been documented after the start of oral treatment with aluminium hydroxide.8
The search for an effective phosphate binding agent for patients with impaired renal function that would not result in appreciable accumulation of aluminium led us to examine the basic aluminium salt of sucrose octasulphate (sucralfate). This drug has recently been described for use in the treatment of peptic ulceration, and claims have been made that it is at least as effective as cimetidine.9 'o It is not an antacid, and its action has been attributed to the formation of an intragastric paste that binds to tissue protein at the base of the ulcer crater. The paste also adsorbs pepsinogen and bile acids, and long term studies have indicated that little or no systemic aluminium absorption occurs in patients with ulcers and normal renal function.'"
We conducted a comparative study of aluminium hydroxide and sucralfate in 12 patients receiving dialysis, assessing both phosphate binding ability and absorption of aluminium.
Patients and methods
We studied 12 patients with end stage chronic renal failure who had been maintained on regular dialysis for more than four months (mean 10 months). Six patients were receiving continuous ambulatory peritoneal dialysis (four exchanges a day) and six hospital haemodialysis (12 hours a week). All patients were receiving regular oral aluminium hydroxide (Alu-cap, Riker), the mean dosage being six capsules a day. Table I 2-001i 1-00 *Aluminium concentrations in dialysate: haemodialysis 0-7 ,mol/l (1-9 ,tg/100 ml);
continuous ambulatory peritoneal dialysis <0 1 ,mol/l (0-3 Wtg/100 ml). Conversion: SI to traditional units-Phosphate: 1 mmol/l 3-1 mg/100 ml. Calcium: 1 mmol/ 14 mg/100 ml. Aluminium: 1 ,mol/1 2-7 ,g/100 ml. Table II shows the results. Serum calcium concentrations were not affected when patients stopped taking aluminium hydroxide or when they took sucralfate instead. Serum phosphate concentrations were adequately controlled with aluminium hydroxide but showed a significant rise (p < 00125) in all patients after aluminium hydroxide was stopped followed by an equally significant fall when sucralfate was taken. Baseline aluminium concentrations were comparable in both groups of patients. Three weeks after aluminium hydroxide was stopped they showed a significant fall (p < 0 0125) in both groups, which was slightly greater in the patients receiving continuous ambulatory peritoneal dialysis. After three weeks of treatment with sucralfate concentrations had risen significantly (p<001), reaching baseline values.
Results
Patients tolerated both forms of treatment well, though some found sucralfate difficult to swallow. Two patients with proved chronic duodenal ulceration obtained almost complete remission of their dyspeptic symptoms, and one was able to stop taking ranitidine.
Discussion
This study suggests that sucralfate is a phosphate binding agent comparable in potency with aluminium hydroxide and indicates that it may have a useful place in the management of hyperphosphataemia in uraemia.
Aluminium may be absorbed from the gastrointestinal tract in quite large quantities after administration of aluminium hydroxide." As most 'free' aluminium exists when aluminium hydroxide is exposed to acid pH conditions, absorption probably occurs in the stomach, although Berlyne et al suggested that the intestine was the most likely site.7 Elimination from the body depends on intact renal function, and appreciable concentrations accumulate in chronic renal failure.' 2 The presence of high aluminium concentrations in dialysate used in haemodialysis6 or continuous ambulatory peritoneal dialysis'4 has been associated with serious toxic consequences. Our finding of a fall in serum aluminium concentration three weeks after treatment with aluminium hydroxide was stopped accords with the finding of Fleming et al' and provides yet further confirmation of the appreciable contribution made by oral administration of aluminium to systemic accumulation in uraemia. We should point out, however, that basal aluminium concentrations at the start of our study were below the ranges previously documented as toxic.6
Several observers have commented that serum aluminium concentrations are lower in continuous ambulatory peritoneal dialysis than haemodialysis.'" Suggested reasons are that continuous ambulatory peritoneal dialysis removes phosphate more completely, so that less aluminium hydroxide is required, or that dialysate concentrations of aluminium are very low, promoting better removal.15 In our survey aluminium hydroxide requirements and basal aluminium concentrations were similar in both groups but when aluminium hydroxide was stopped the serum aluminium concentration appeared to fall further in patients receiving continuous ambulatory peritoneal dialysis in whom the dialysate aluminium concentration was considerably lower.
Nagashima and Yoshida suggested that because of the formation of a paste in the stomach and the physicochemical properties of sucralfate in acid media few or no aluminium ions should be available for absorption.'6 In long term studies in patients with peptic ulcer and normal renal function Kinoshita et al could not show any rise in serum aluminium concentrations,'1 although urine aluminium concentrations were not measured so that efficient renal clearance may have masked appreciable absorption. Our results indicate that absorption of aluminium with sucralfate was much the same as that with aluminium hydroxide. We were unable to determine accurately whether the presence of peptic ulceration might diminish absorption of aluminium, although serum aluminium concentrations were not apparently lower in our two subjects with peptic ulcer disease.
The ulcer healing properties of sucralfate indicate that it may be the phosphate binder of choice in uraemic patients with peptic ulcers. Certainly, two of our subjects with proved duodenal ulcers experienced improvement in dyspeptic symptoms. Because of its effective phosphate binding action sucralfate may cause the same kind of hypophosphataemic mineral metabolic upset encountered with antacid treatment, and caution should be exercised with the use of large doses in patients with normal renal function.'7 
Introduction
The sweat test is accepted as an essential diagnostic test for cystic fibrosis in childhood. Normal adults have a higher sweat sodium concentration than normal children, and the test may therefore be less reliable in adults.! Di Sant'Agnese and Davis stated, however, that the criteria for diagnosing cystic fibrosis were similar in adults and children-namely, the presence of raised sweat chloride and sodium (>50-60 mmol(mEq)/l) concentrations and either chronic pulmonary disease or pancreatic sufficiency.2 Shwachman et al commented that "one can interpret the sweat test in adults with the same degree of reliability as in children."3 Modifications of the sweat test using aldosterone or fludrocortisone have been advocated.4 Most of these reports, however, concern children rather than adults. The aim of the present study was to define a sweat sodium concentration in adults that could be taken as diagnostic of cystic fibrosis and to study the effect of fludrocortisone on sweat sodium concentrations in normal adults and adults with cystic fibrosis.
Subjects and methods
Sweat tests were performed on 25 patients with cystic fibrosis (10 male, 15 female; age range . The controls consisted of 25 fit adults (13 men, 12 women; age range 19-40). Sweat tests were performed using pilocarpine iontophoresisG and the sodium concentration measured by flame photometry. All sweat tests were performed by a laboratory scientific officer or a nursing sister experienced in the technique. In each case over 100 mg sweat was collected. Great care was taken that the filter paper was not contaminated by the investigator's sweat, and while sweat was being collected the filter paper was completely occluded by an airtight dressing to prevent loss of water by evaporation. All tests were performed in duplicate. Only duplicate readings that did not vary by more than 8 mmol/l were accepted.
Sweat tests were performed on day 1. On days 2 and 3 all 50 subjects received 5 mg fludrocortisone, and on days 4 and 5 the sweat tests were repeated. Fig 1 shows the results of the sweat tests over the five days in two controls and two patients with cystic fibrosis. The baseline value on day 1 and the lowest concentration reached on either day 4 or day 5 were recorded; the percentage suppression was calculated from these values. Statistical analysis was by discriminant analysis.7
Results
The mean ( j -2 SD) baseline sweat sodiuimn concentration was Statistical analysis of the overlap between the distribution-s indicated that if a baseline sweat sodium concentration of above 60 mmol/l was regarded as being diagnostic of cystic fibrosis 17-11% of controls and 0-34() of patients would be misclassified; and if 70 mmol/l was used 6-430o of controls and 1-88% of patients would
